XORTX THERAPEUTICS INC (XRTX.CA) Stock Fundamental Analysis

Canada • TSX Venture Exchange • TSX-V:XRTX • CA98420Q3061

0.58 CAD
-0.05 (-7.94%)
Last: Feb 6, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

1

Overall XRTX gets a fundamental rating of 1 out of 10. We evaluated XRTX against 33 industry peers in the Pharmaceuticals industry. While XRTX seems to be doing ok healthwise, there are quite some concerns on its profitability. XRTX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year XRTX has reported negative net income.
  • XRTX had a negative operating cash flow in the past year.
  • In the past 5 years XRTX always reported negative net income.
  • XRTX had a negative operating cash flow in each of the past 5 years.
XRTX.CA Yearly Net Income VS EBIT VS OCF VS FCFXRTX.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

  • XRTX has a worse Return On Assets (-69.13%) than 78.79% of its industry peers.
  • With a Return On Equity value of -98.46%, XRTX is not doing good in the industry: 69.70% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -69.13%
ROE -98.46%
ROIC N/A
ROA(3y)-60.92%
ROA(5y)-49.27%
ROE(3y)-85.37%
ROE(5y)-73.65%
ROIC(3y)N/A
ROIC(5y)N/A
XRTX.CA Yearly ROA, ROE, ROICXRTX.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for XRTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XRTX.CA Yearly Profit, Operating, Gross MarginsXRTX.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • XRTX has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, XRTX has less shares outstanding
  • Compared to 1 year ago, XRTX has a worse debt to assets ratio.
XRTX.CA Yearly Shares OutstandingXRTX.CA Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M
XRTX.CA Yearly Total Debt VS Total AssetsXRTX.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

  • Based on the Altman-Z score of -10.16, we must say that XRTX is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -10.16, XRTX is doing worse than 81.82% of the companies in the same industry.
  • XRTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -10.16
ROIC/WACCN/A
WACCN/A
XRTX.CA Yearly LT Debt VS Equity VS FCFXRTX.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M

2.3 Liquidity

  • XRTX has a Current Ratio of 1.62. This is a normal value and indicates that XRTX is financially healthy and should not expect problems in meeting its short term obligations.
  • The Current ratio of XRTX (1.62) is comparable to the rest of the industry.
  • XRTX has a Quick Ratio of 1.62. This is a normal value and indicates that XRTX is financially healthy and should not expect problems in meeting its short term obligations.
  • XRTX has a better Quick ratio (1.62) than 66.67% of its industry peers.
Industry RankSector Rank
Current Ratio 1.62
Quick Ratio 1.62
XRTX.CA Yearly Current Assets VS Current LiabilitesXRTX.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. Growth

3.1 Past

  • The earnings per share for XRTX have decreased strongly by -1213.33% in the last year.
EPS 1Y (TTM)-1213.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.88%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-11.64%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
XRTX.CA Yearly EPS VS EstimatesXRTX.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 -2 -4 -6 -8

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • XRTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year XRTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XRTX.CA Price Earnings VS Forward Price EarningsXRTX.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XRTX.CA Per share dataXRTX.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for XRTX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

XORTX THERAPEUTICS INC

TSX-V:XRTX (2/6/2026, 7:00:00 PM)

0.58

-0.05 (-7.94%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-14
Earnings (Next)03-30
Inst Owners1.45%
Inst Owner ChangeN/A
Ins Owners1.87%
Ins Owner ChangeN/A
Market Cap4.04M
Revenue(TTM)N/A
Net Income(TTM)-1.94M
Analysts80
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.5
P/tB 1.66
EV/EBITDA N/A
EPS(TTM)-0.65
EYN/A
EPS(NY)-2.12
Fwd EYN/A
FCF(TTM)-0.59
FCFYN/A
OCF(TTM)-0.58
OCFYN/A
SpS0
BVpS0.39
TBVpS0.35
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -69.13%
ROE -98.46%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-60.92%
ROA(5y)-49.27%
ROE(3y)-85.37%
ROE(5y)-73.65%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 31.78%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.62
Quick Ratio 1.62
Altman-Z -10.16
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)48.3%
Cap/Depr(5y)87.61%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1213.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.88%
EPS Next Y-11.64%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y27.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-29.82%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y67.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y67.46%
OCF growth 3YN/A
OCF growth 5YN/A

XORTX THERAPEUTICS INC / XRTX.CA FAQ

What is the ChartMill fundamental rating of XORTX THERAPEUTICS INC (XRTX.CA) stock?

ChartMill assigns a fundamental rating of 1 / 10 to XRTX.CA.


What is the valuation status of XORTX THERAPEUTICS INC (XRTX.CA) stock?

ChartMill assigns a valuation rating of 0 / 10 to XORTX THERAPEUTICS INC (XRTX.CA). This can be considered as Overvalued.


Can you provide the profitability details for XORTX THERAPEUTICS INC?

XORTX THERAPEUTICS INC (XRTX.CA) has a profitability rating of 0 / 10.


What is the financial health of XORTX THERAPEUTICS INC (XRTX.CA) stock?

The financial health rating of XORTX THERAPEUTICS INC (XRTX.CA) is 5 / 10.


What is the earnings growth outlook for XORTX THERAPEUTICS INC?

The Earnings per Share (EPS) of XORTX THERAPEUTICS INC (XRTX.CA) is expected to decline by -11.64% in the next year.